Tetrapyrroles and derivatives

Abcam Flupirtine maleate, Neuronal potassium channel opener, 25MG

MW 420.4 Da, Purity >99%. Neuronal potassium channel opener. Activates Kv7.2 channels and potently activates the inwardly rectifying potassium current (KIR; EC₅₀ = 600 nM). Centrally acting, non-opiate analgesic. Neuroprotective and antiapoptotic agent. Also has muscle relaxant properties. Active in vivo.

The product is subject to the following: Abcam Restricted Use Statement

Abcam Flupirtine maleate, Neuronal potassium channel opener, 100MG

MW 420.4 Da, Purity >99%. Neuronal potassium channel opener. Activates Kv7.2 channels and potently activates the inwardly rectifying potassium current (KIR; EC₅₀ = 600 nM). Centrally acting, non-opiate analgesic. Neuroprotective and antiapoptotic agent. Also has muscle relaxant properties. Active in vivo.

The product is subject to the following: Abcam Restricted Use Statement

Abcam Flupirtine maleate, Neuronal potassium channel opener, 10MG

MW 420.4 Da, Purity >99%. Neuronal potassium channel opener. Activates Kv7.2 channels and potently activates the inwardly rectifying potassium current (KIR; EC₅₀ = 600 nM). Centrally acting, non-opiate analgesic. Neuroprotective and antiapoptotic agent. Also has muscle relaxant properties. Active in vivo.

The product is subject to the following: Abcam Restricted Use Statement

Abcam x E-991 dihydrochloride, KCNQ channel blocker; blocks M current, 50MG

MW 449.4 Da, Purity >99%. Potent and selective blocker of KCNQ voltage-gated potassium channels. Blocks M current. (IC₅₀ values are 0.98 μM (M-current), 0.71 μM (KCNQ 2), 0.75 μM (KCNQX 1), >100 μM (Kv1.2) and >43 μM (Kv4.3). Potent pulmonary vasoconstrictor. Cognitive enhancer following oral administration in vivo.

The product is subject to the following: Abcam Restricted Use Statement